Up-front melphalan in Ewing's family tumors with bone/bone marrow metastases at onset (very-high risk EFTs). A report from ISG/AIEOP "Very High Risk EFTs Cooperative Study".


9037 Background:Patients with very-high risk EFTs have a poor prognosis. Melphalan (L-PAM) has been widely used in myeloablative regimens in EFTs, without a prior demonstration of its effectiveness in this disease. METHODS From March 2001, a study was opened for very-high risk EFTs with the main aim to investigate the activity and toxicity of up-front L… (More)


  • Presentations referencing similar topics